RT Journal Article
SR Electronic
T1 Biological Evaluation of Molecules of the azaBINOL Class as Antiviral Agents: Specific Inhibition of HIV-1 RNase H Activity by 7-Isopropoxy-8-(naphth-1-yl)quinoline
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 525105
DO 10.1101/525105
A1 Ross D. Overacker
A1 Somdev Banerjee
A1 George F. Neuhaus
A1 Selena Milicevic Sephton
A1 Alexander Herrmann
A1 James A. Strother
A1 Ruth Brack-Werner
A1 Paul R. Blakemore
A1 Sandra Loesgen
YR 2019
UL http://biorxiv.org/content/early/2019/01/23/525105.abstract
AB Inspired by bioactive biaryl-containing natural products found in plants and the marine environment, a series of synthetic compounds belonging to the azaBINOL chiral ligand family was evaluated for antiviral activity against HIV-1. Testing of 39 unique azaBINOLs in a singleround infectivity assay resulted in the identification of three promising antiviral compounds, including 7-isopropoxy-8-(naphth-1-yl)quinoline (azaBINOL B#24), which exhibited low-micromolar activity. The active compounds and several close structural analogues were further tested against three different HIV-1 envelope pseudotyped viruses as well as in a full-virus replication system (EASY-HIT). Mode-of-action studies using a time-of-addition assay indicated that azaBINOL B#24 acts after viral entry but before viral assembly and budding. HIV-1 reverse transcriptase (RT) assays that individually test for polymerase and RNase H activity were used to demonstrate that B#24 inhibits RNase H activity, most likely allosterically. Further binding analysis using bio-layer interferometry (BLI) showed that B#24 interacts with HIV-1 RT in a highly specific manner. These results indicate that azaBINOL B#24 is a potentially viable, novel lead for the development of new HIV-1 RNase H inhibitors. Furthermore, this study demonstrates that the survey of libraries of synthetic compounds, designed purely with the goal of facilitating chemical synthesis in mind, may yield unexpected and selective drug leads for the development of new antiviral agents.